Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Artificial Intelligence-Generated Electronic Medical Record Summarization in Breast Surgical Oncology.

Annals of surgical oncology·2026

Same author

Visceral adiposity and breast cancer outcomes: transcriptomic analysis of the tumor microenvironment by intrinsic subtype.

Breast cancer research : BCR·2026

Same author

Worsening frailty and declining quality of life in older survivors of non-metastatic breast cancer.

Journal of the National Cancer Institute·2026

Same author

Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.

JAMA oncology·2026

Same author

ASO Visual Abstract: From Clinical Trial Awareness to Practice-Factors Associated with Intent to Omit Axillary Surgery Based on the SOUND Clinical Trial.

Annals of surgical oncology·2026

Same author

Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer.

medRxiv : the preprint server for health sciences·2026

Search research articles

Related Experiment Video

Updated: Jan 7, 2026

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Published on: May 17, 2024

Breast-Conserving Therapy for Multiple Ipsilateral Breast Cancer After Neoadjuvant Systemic Therapy.

Monika K Masanam^1,2,3, Jennifer R Bellon^2,3,4, José P Leone^2,3,5

¹Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA, USA.

Annals of Surgical Oncology

|January 4, 2026

Summary

Breast-conserving surgery (BCS) is safe for multiple ipsilateral breast cancer (MIBC) patients receiving neoadjuvant systemic therapy (NST). Local recurrence rates for MIBC after BCS and NST were similar to those with unifocal disease.

Keywords:

Breast-conserving surgery Multiple ipsilateral breast cancer Neoadjuvant systemic therapy

More Related Videos

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Related Experiment Videos

Last Updated: Jan 7, 2026

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Published on: May 17, 2024

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Area of Science:

Oncology
Surgical Oncology
Breast Cancer Research

Background:

Previous trials established breast-conserving surgery (BCS) safety for multiple ipsilateral breast cancer (MIBC) with upfront surgery.
The oncologic safety of BCS in MIBC patients receiving neoadjuvant systemic therapy (NST) remained uncertain.

Purpose of the Study:

To evaluate the safety and oncologic outcomes of BCS in patients with MIBC who underwent NST.
To compare local recurrence (LR) rates between MIBC and unifocal breast cancer patients treated with BCS after NST.

Main Methods:

Retrospective analysis of 1515 patients (73 with MIBC, 1442 with unifocal disease) who underwent BCS after NST (2016-2023).
MIBC defined preoperatively as 2-3 foci with ≥2 cm intervening normal tissue.
Outcomes assessed included local recurrence, distant recurrence, and breast cancer mortality.

Main Results:

No significant differences in LR (1.4% vs. 3.1%), distant recurrence (5.5% vs. 4.6%), or breast cancer mortality (4.1% vs. 2.6%) between MIBC and unifocal groups.
MIBC patients underwent single-site (65.8%), two-site (31.5%), or three-site (2.7%) lumpectomies.
Median follow-up was 34.7 months.

Conclusions:

BCS is a safe surgical option for well-selected MIBC patients undergoing NST.
The oncologic outcomes of BCS after NST for MIBC are comparable to those for unifocal breast cancer.